ACUMEN PHARMACEUTICALS INC (ABOS) Stock Analyst Ratings
USA - NASDAQ:ABOS - US00509G2093 - Common Stock
1.9 USD
-0.13 (-6.4%)
1.9 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 89% to ABOS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.67. This target is 356.32% above the current price.
ABOS was analyzed by 11 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about ABOS.
In the previous month the buy percentage consensus was at a similar level.
ABOS was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-25 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-17 | Citigroup | Initiate | Buy |
| 2025-03-28 | UBS | Maintains | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | UBS | Maintains | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-25 | Citigroup | Initiate | Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-12 | Deutsche Bank | Initiate | Buy |
| 2023-08-09 | Credit Suisse | Reiterate | Outperform -> Outperform |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-20 | B of A Securities | Reiterate | Buy |
| 2023-07-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-18 | Cantor Fitzgerald | Initiate | Overweight |
| 2023-03-28 | Credit Suisse | Maintains | Outperform |
| 2023-03-28 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-02 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | Credit Suisse | Maintains | Outperform |
| 2022-10-05 | BTIG | Maintains | Buy |
| 2022-07-15 | BTIG | Initiate | Buy |
| 2022-06-30 | HC Wainwright & Co. | Initiate | Buy |
| 2022-01-21 | B of A Securities | Upgrade | Neutral -> Buy |
| 2021-07-26 | UBS | Initiate | Buy |
| 2021-07-26 | Stifel | Initiate | Buy |
| 2021-07-26 | Credit Suisse | Initiate | Outperform |
| 2021-07-26 | B of A Securities | Initiate | Neutral |
ACUMEN PHARMACEUTICALS INC / ABOS FAQ
What is the price target for ABOS stock?
11 analysts have analysed ABOS and the average price target is 8.67 USD. This implies a price increase of 356.32% is expected in the next year compared to the current price of 1.9.
Can you provide the consensus rating for ACUMEN PHARMACEUTICALS INC stock?
The consensus rating for ACUMEN PHARMACEUTICALS INC (ABOS) is 89.0909 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed ACUMEN PHARMACEUTICALS INC (ABOS)?
The number of analysts covering ACUMEN PHARMACEUTICALS INC (ABOS) is 11.